Sigvotatug Vedotin
Sigvotatug Vedotin is a pharmaceutical drug with 5 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
0
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
4
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Clinical Trials (5)
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5